



Maine Department of Health and Human Services

MaineCare Services

Pharmacy Unit

11 State House Station

PAUL R. LEPAGE
GOVERNOR

BETHANY L. HAMM
ACTING COMMISSIONER

Pharmacy Benefit Update
Fall/Winter 2018 Issue



Preferred Drug List (PDL) News

PDL Changes: This issue of the Pharmacy Benefit Updates contains information about changes to the Preferred Drug List for January 1, 2019, as well as updates on MaineCare pharmacy benefit changes.

Non-Preferred			
ADZENYS ER	ADZENYS XR- ODT	APTENSIO XR	ARANESP
ARIPIRAZOLE ODT	ARIPIRAZOLE SOL	ASPIRIN-DIPYRIDAMOLE ER CPMP 12HR	AZOR TAB
BACITRACIN OINT	BLEPHAMIDE DROPS SUSP	BUDESONIDE NEB 1MG	CARBAMAZEPINE XR
CARBATROL	CEFPODOXIME PROXETIL TAB	CLIMARA PATCH	CEFPODOXIME PROXETIL SUS
CLOZAPINE ODT	COTEMPLA XR- ODT	DEXAMETHASONE SODIUM PHOSPHATE DROPS SUSP	DEXTROAMPHETAMINE SULFATE TAB
DICLOFENAC GEL	DICLOFENAC OPTH	DICLOFENAC OPTH 0.1%	EPIVIR
ESTRADIOL-NORETHINDRONE	FERRALET 90	FONDAPARINUX	FRAGMIN SYRINGE
FRAGMIN VIAL	FUSION PLUS	GABITRIL TAB	HEMOCYTE PLUS
HUMULIN N VIAL	HUMULIN R VIAL	HYDROMORPHONE ER	INTEGRA F
INTEGRA PLUS	ISENTRESS TAB	KOGENATE FS	LAMOTRIGINE ER ODT
LOTEMAX DROPS GEL	MENEST TAB	METHITEST TAB	METHYLPHENIDATE CD CAP
METHYLPHENIDATE LA CAP	MICONAZOLE 3 KIT	NEOMYCIN-POLY-GRAMICIDIN DROPS	NORETHINDRON-ETHINYL
OLOPATADINE HCL 0.2%	PALIPERIDONE ER	PREDNISOLONE SODIUM PHOSPHATE DROPS	PULMICORT
QUDEXY XR	SULFACETAMIDE SODIUM DROPS	SULFACETAMIDE SODIUM OINT	TANDEM PLUS
TEGRETOL TAB	TERCONAZOLE CREAM	TIMOLOL DROP DAILY	TIMOLOL SOL-GEL
TRACLEER TAB SUSP	TRILEPTAL SUS	URECHOLINE TAB	VIREAD TAB
VIVELLE-DOT PATCH			
Preferred			
ACTIVELLA TAB	ACULAR DROPS .5%	ADCIRCA	ADVAIR DISKUS
ADVATE VIAL	ALORA PATCH	ASMANEX	AUSTEDO TAB
BUDESONIDE NEB 0.25MG & 0.5MG	CLOTRIMAZOLE-3 CREAM	COLY-MYCIN S DROPS SUSP	COLYTE
COMBIPATCH	DELZICOL CAP	DERMA-SMOOTH-FS OIL	DICLEGIS
DYANAVAL XR	EPOGEN VIAL	EUCRISA	FIRAZYR SYRINGE
FLECTOR PATCH	FLOVENT DISK	FOCALIN TAB	JARDIANCE
LAMIVUDINE	LOTRONEX TAB	LUMIGAN DROPS	LYRICA CAP
METHYLPHENIDATE TAB	MICONAZOLE 3 KIT OTC	MOVANTIK	NEUPOGEN VIAL



Maine Department of Health and Human Services

MaineCare Services

Pharmacy Unit

11 State House Station

PAUL R. LEPAGE
GOVERNOR

BETHANY L. HAMM
ACTING COMMISSIONER

NEVANAC DROPS SUSP	NICOTINE LOZENGE	NICOTINE LOZENGE MINI	OFLOXACIN DROPS
PEG 3350-ELECTROLYTE SOL	PENNSAID	PRALUENT PEN	PRASUGREL HCL TAB
PRED-G DROPS SUSP	PRED-G OINT	PROAIR HFA	PROAIR RESPICLICK
RESTASIS	RHOPRESSA DROPS	RISPERIDONE ODT	RIZATRIPTAN RAPDIS
ROCALTROL SOL	SKLICE	SYNAREL NASAL SPRAY	SYNJARDY
SYNJARDY XR	TOBRAMYCIN DROPS	TOBEX OINT	TOPIRAMATE ER CAP
TROGARZO (CLINICAL PA)	TUDORZA PRESSAIR	TYBOST	VIBERZI
VOLTAREN GEL	WARFARIN	XENAZINE TAB	

For a complete list of PDL changes and criteria, please go to www.mainearepdl.com



Narcan Nasal Spray Update

Narcan (Naloxone nasal spray) has been available without a Prior Authorization (PA) on the MaineCare PDL since September 2016. MaineCare members are permitted two (2) units (a two-pack) every 28 days with a prescription. Narcan is an important tool in battling the opioid crisis. Providers are encouraged to co-prescribe Narcan when clinically appropriate to do so (AMA Opioid Task Force, August 2017).



Prior Authorization (PA) Statistics

Top Five Specialty Drugs by PA	Top Five Drugs by PA
MAVYRET	SUBOXONE
NEXPLANON	OMEPRAZOLE
MAKENA	OXYCODONE HCL
CREON	ADDERALL XR
HUMIRA PEN	MELATONIN



FDA Alerts

General Anesthetic and Sedation Drugs: Drug Safety Communication - New Warnings for Young Children and Pregnant Women:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm533195.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery



Maine Department of Health and Human Services

MaineCare Services

Pharmacy Unit

11 State House Station

PAUL R. LEPAGE
GOVERNOR

BETHANY L. HAMM
ACTING COMMISSIONER

FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease:

<https://www.fda.gov/Drugs/DrugSafety/ucm576656.htm>

FDA Drug Safety Communication: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older:

https://www.fda.gov/Drugs/DrugSafety/ucm590435.htm?utm_campaign=Prescription%20Opioid%20Cough%20and%20Cold%20Medicines%3A%20Drug%20Safety%20Communication&utm_medium=email&utm_source=Eloqua&elqTrackId=247340cdc952492aa2ac3f68787f07d2&elq=f03d18cf9197472cb8952df262e8a821&elqaid=2050&elqat=1&elqCampaignId=1403

Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics:

<https://www.fda.gov/Drugs/DrugSafety/ucm608265.htm>

Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction:

<https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm605628.htm>

Juluca, Tivicay, Triumeq (dolutegravir): FDA to Evaluate - Potential Risk of Neural Tube Birth Defects:

https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm608168.htm?utm_campaign=FDA%20MedWatch%20-%20Juluca%2C%20Tivicay%2C%20Triumeq&utm_medium=email&utm_source=Eloqua

Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy:

<https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm608253.htm>

FDA warns about increased risk of cancer relapse with long-term use of azithromycin (Zithromax, Zmax) antibiotic after donor stem cell transplant:

<https://www.fda.gov/Drugs/DrugSafety/ucm614085.htm>

FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes:

<https://www.fda.gov/Drugs/DrugSafety/ucm611032.htm>

FDA In Brief: FDA takes additional action to mitigate shortages of EpiPen by extending expiration date for specific lots of medication:



**Maine Department of Health and Human Services
MaineCare Services
Pharmacy Unit
11 State House Station**

**PAUL R. LEPAGE
GOVERNOR**

**BETHANY L. HAMM
ACTING COMMISSIONER**

https://www.fda.gov/NewsEvents/Newsroom/FDAInBrief/ucm617724.htm?utm_campaign=FDA%20takes%20additional%20action%20to%20mitigate%20shortages%20of%20EpiPen%20%28epinephrine%29%20auto-injector%20by%20extending&utm_medium=email&utm_source=Eloqua

**SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication -
Regarding Rare Occurrences of a Serious Infection of the Genital Area:**

<https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm618908.htm>



Next Drug Utilization Review (DUR) Committee Meeting

Comments on the PDL or any PAs, either proposed or already in effect, may be made at these meetings or by e-mail, letter, or phone if more convenient.

For DUR questions, you may contact:

Jill Kingsbury, Director of Pharmacy, MaineCare Services
Jill.Kingsbury@maine.gov

For PA/PDL questions, you may contact:

Michael Ouellette, R.Ph mouellette@changehealthcare.com

Jeffrey Barkin, MD jbarkin@changehealthcare.com

Date: March 13, 2019

Time: 5:30-8:30pm

Location: The Armory,
Augusta